IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.

Trial Details

NCT ID
NCT04562129
Phase
PHASE2
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Interleukin-2
  • Ipilimumab
  • Nivolumab
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Histologically or cytologically confirmed metastatic melanoma. This includes American Joint Committee on Cancer (AJCC) stage IV or advanced/inopera…
  • Measurable disease, according to RECIST version 1.1
  • Must be free of active brain metastasis by contrast-enhanced CT/MRI scans within 4 weeks prior to enrollment. If known to have prior brain metastas…
  • Must have previously received anti-PD1 immunotherapy (nivolumab or pembrolizumab) and later experienced disease progression.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →